Loading clinical trials...
Loading clinical trials...
A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography
Conditions
Interventions
Dalcetrapib
Placebo
Locations
110
United States
Los Angeles, California, United States
Los Angeles, California, United States
Torrance, California, United States
Boulder, Colorado, United States
Greeley, Colorado, United States
Littleton, Colorado, United States
Start Date
January 1, 2010
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
March 24, 2020
NCT07547098
NCT06675552
NCT07491315
NCT07487363
NCT07256249
NCT03372733
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions